The perks of combining extension and Gleason score of positive surgical margins after robot-assisted radical prostatectomy

  • 0Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, Milan, Italy. stefano.m.tappero@gmail.com.

|

|

Summary

This summary is machine-generated.

Extensive positive surgical margins with high Gleason scores in prostate cancer patients undergoing robot-assisted radical prostatectomy are linked to worse oncological outcomes, including PSA persistence and recurrence. These findings aid in patient counseling and treatment decisions.

Area Of Science

  • Urology
  • Oncology
  • Surgical Pathology

Background

  • The prognostic significance of positive surgical margins (PSM) features in prostate cancer (PCa) remains unclear.
  • This study investigates the impact of PSM extension and Gleason score (GS) on outcomes after robot-assisted radical prostatectomy (RARP).

Purpose Of The Study

  • To assess the association between PSM characteristics and PSA persistence, biochemical recurrence (BCR), and clinical recurrence (CR) in PCa patients.
  • To stratify PSM based on extension (focal/extensive) and GS (3 or 4-5).

Main Methods

  • Retrospective analysis of 2617 PCa patients from six European centers who underwent RARP.
  • Patients were categorized by PSM status and features (negative, focal/extensive GS 3, focal/extensive GS 4-5).
  • Statistical models (logistic regression, Cox regression) were used to evaluate PSA persistence, BCR, and CR.

Main Results

  • 30% of patients had PSM, with 69% having GS 4-5 and 51% having focal extension.
  • PSA persistence was associated with focal and extensive PSM-GS 4-5 (OR 1.57-2.17).
  • Extensive PSM-GS 4-5 independently predicted BCR (HR 2.53) and CR (HR 1.45).

Conclusions

  • Prostate cancer patients with extensive positive surgical margins and high Gleason scores (GS 4-5) experience poorer oncological outcomes.
  • These findings are crucial for improving patient counseling and guiding decisions on adjuvant therapies.